Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Avenir Wellness Solutions Inc AVRW

Avenir Wellness Solutions, Inc. is a platform technology company. The Company develops proprietary wellness, nutraceutical, and topical delivery systems. The Company is focused on the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve wellness. Its wholly owned subsidiary, The Sera Labs, Inc. (Sera Labs), is engaged the development, production... see more

OTCQB:AVRW - Post Discussion

Avenir Wellness Solutions Inc > CURE partnership with Canopy Growth
View:
Post by adamchess on Sep 12, 2018 12:11pm

CURE partnership with Canopy Growth

https://ca.proactiveinvestors.com/companies/stocktube/10439/cure-pharmaceutical-joins-forces-with-canopy-growth-in-exclusive-partnership-10439.html

CURE Pharmaceutical joins forces with Canopy Growth in exclusive partnership 

CURE Pharmaceutical Holding Corp (OTCMKTS:CURR) COO Jessica Rousset tells Proactive Investors the drug manufacturing company has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE's patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.

Rousset says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities